| Darolutamide studied in …STUDIED_INderived96 of 96show fewer |
|---|
| → studied in | NCT04736199Phase 3 · completed Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer · 96 trials list this drug (63 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07190300Phase 1/Phase 2 · recruiting TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03568656Phase 1/Phase 2 · completed Study to Evaluate CCS1477 in Advanced Tumours · 96 trials list this drug (63 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05818683Phase 1 · recruiting A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06334120recruiting An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04335682Phase 2 · completed Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05059236Phase 2 · completed A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. · 96 trials list this drug (63 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07620041Phase 1 · recruiting Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05762536Phase 2 · recruiting Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07723248Phase 3 · recruiting A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04558866Phase 2 · completed Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05367440Phase 1/Phase 2 · active not recruiting Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07611110Phase 3 · recruiting AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07538843recruiting An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314324Phase 2 · completed A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050084Phase 3 · active not recruiting Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial · 96 trials list this drug (63 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05519449Phase 1 · recruiting Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07450599Phase 2 · recruiting A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04122976active not recruiting A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05676203Phase 3 · active not recruiting A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05669664Phase 2 · active not recruiting Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers · 96 trials list this drug (63 active) | — | — | Salivary Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06625970Phase 3 · recruiting Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120491Phase 3 · active not recruiting Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04484818Phase 3 · active not recruiting Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study · 96 trials list this drug (63 active) | — | — | Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06169124Phase 2 · active not recruiting Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors · 96 trials list this drug (63 active) | — | — | Adult Ovarian Granulosa Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07730151Phase 2 · not yet recruiting Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717099Phase 2 · not yet recruiting Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06378866Phase 2 · recruiting Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma,Castration-Sensitive Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711002Phase 3 · not yet recruiting Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06592924Phase 3 · recruiting Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05413421Phase 1 · recruiting Study of ORIC-944 in Patients With Metastatic Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464226Phase 3 · active not recruiting Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer · 96 trials list this drug (63 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05794906Phase 3 · active not recruiting A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07344779active not recruiting A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07406282recruiting A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics · 96 trials list this drug (63 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05348876Phase 4 · recruiting A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07140900Phase 1 · recruiting Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06401980Phase 2 · recruiting Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05938270Phase 1 · completed A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05999968Phase 1 · terminated Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment · 96 trials list this drug (63 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06220864Phase 1 · recruiting SNV1521 in Participants With Advanced Solid Tumors · 96 trials list this drug (63 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05617885Phase 1 · completed Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07027124Phase 2 · recruiting Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07617272Phase 2 · recruiting Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04070209Phase 2 · active not recruiting Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07244341Phase 1 · recruiting A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04136353Phase 3 · active not recruiting Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04916613Phase 3 · recruiting ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925648Phase 2 · completed Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06190899Phase 1/Phase 2 · recruiting Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer · 96 trials list this drug (63 active) | — | — | Prostate Neoplasm,Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05694819Phase 2 · completed Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) · 96 trials list this drug (63 active) | — | — | Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282588Phase 2/Phase 3 · recruiting Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07428642completed PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC. · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476677Phase 2 · not yet recruiting Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06173362Phase 2 · recruiting Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer · 96 trials list this drug (63 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05526248Phase 2 · completed A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07142551Phase 2 · recruiting Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06463457Phase 2 · active not recruiting Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06724159recruiting Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. · 96 trials list this drug (63 active) | — | — | Malignant Genitourinary System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627530Phase 4 · active not recruiting COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06631521Phase 1 · recruiting Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06660862Phase 4 · not yet recruiting Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer. · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04025372Phase 2 · active not recruiting INTREPId (INTermediate Risk Erection PreservatIon Trial) · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07282197Phase 2 · not yet recruiting Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07016399Phase 2 · recruiting Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC · 96 trials list this drug (63 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02972060Phase 2 · active not recruiting ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03385655Phase 2 · active not recruiting Prostate Cancer Biomarker Enrichment and Treatment Selection · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04319783Phase 2 · active not recruiting Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202301completed A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06013475completed An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03903835Phase 3 · recruiting ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06652607recruiting PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06276465Phase 3 · recruiting Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03724747Phase 1 · completed Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer · 96 trials list this drug (63 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06575257Phase 2 · recruiting Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06473259recruiting Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients · 96 trials list this drug (63 active) | — | — | Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06430411not yet recruiting Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study · 96 trials list this drug (63 active) | — | — | Prostate Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06204302completed An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05362149completed An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02933801Phase 2 · terminated ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05116475Phase 3 · recruiting Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 96 trials list this drug (63 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04641078Phase 2 · unknown Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04176081Phase 2 · not yet recruiting Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04737109Phase 1/Phase 2 · terminated Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05771896Phase 3 · withdrawn Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900973Phase 2 · unknown A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04157088Phase 2 · terminated Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05249712Phase 2 · unknown Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03383679Phase 2 · completed Study on Androgen Receptor and Triple Negative Breast Cancer · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02200614Phase 3 · completed Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03004534early Phase 1 · completed A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide · 96 trials list this drug (63 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03237416Phase 1 · completed Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers · 96 trials list this drug (63 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01317641Phase 1/Phase 2 · completed Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01429064Phase 2 · completed Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 · 96 trials list this drug (63 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02671097Phase 1 · completed Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate · 96 trials list this drug (63 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |